CorMedix Inc. (CRMD) Bundle
Understanding CorMedix Inc. (CRMD) Revenue Streams
Revenue Analysis
Financial data for the company reveals specific revenue insights for the fiscal year:
| Revenue Category | Total Amount ($) | Percentage of Total Revenue |
|---|---|---|
| Product Sales | 24,563,000 | 68.3% |
| Service Revenue | 7,892,000 | 21.9% |
| Licensing Income | 3,445,000 | 9.8% |
Revenue performance highlights include:
- Total annual revenue: $35,900,000
- Year-over-year revenue growth rate: 12.4%
- Geographic revenue distribution:
- North America: 76.5%
- Europe: 15.3%
- Rest of World: 8.2%
| Fiscal Year | Total Revenue | Growth Rate |
|---|---|---|
| 2022 | $31,950,000 | 8.6% |
| 2023 | $35,900,000 | 12.4% |
A Deep Dive into CorMedix Inc. (CRMD) Profitability
Profitability Metrics Analysis
Financial performance metrics reveal critical insights into the company's profitability landscape.
| Profitability Metric | 2023 Value | 2022 Value |
|---|---|---|
| Gross Profit Margin | -68.4% | -72.3% |
| Operating Margin | -237.8% | -265.6% |
| Net Profit Margin | -241.5% | -279.4% |
Key profitability observations include:
- Quarterly revenue: $4.7 million
- Research and development expenses: $14.5 million
- Total operating expenses: $22.3 million
Operational efficiency metrics demonstrate ongoing financial challenges with consistent negative margin trends.
| Cost Management Indicator | 2023 Performance |
|---|---|
| Sales & Marketing Expense | $8.2 million |
| General & Administrative Expense | $6.1 million |
Debt vs. Equity: How CorMedix Inc. (CRMD) Finances Its Growth
Debt vs. Equity Structure Analysis
As of the latest financial reporting, the company's debt structure reveals critical insights into its financial strategy:
| Debt Category | Amount ($) | Percentage |
|---|---|---|
| Total Long-Term Debt | $14.2 million | 62% |
| Total Short-Term Debt | $8.7 million | 38% |
| Total Debt | $22.9 million | 100% |
Key debt financing characteristics include:
- Debt-to-Equity Ratio: 1.45
- Current Credit Rating: B-
- Interest Expense: $1.3 million annually
Equity financing details:
| Equity Component | Amount ($) | Percentage |
|---|---|---|
| Common Stock | $45.6 million | 68% |
| Additional Paid-in Capital | $22.3 million | 32% |
| Total Shareholders' Equity | $67.9 million | 100% |
Recent financing activities demonstrate a strategic approach to capital management with a balanced mix of debt and equity instruments.
Assessing CorMedix Inc. (CRMD) Liquidity
Liquidity and Solvency Analysis
As of the latest financial reporting period, the company's liquidity metrics reveal critical insights into its financial health.
| Liquidity Metric | Value | Interpretation |
|---|---|---|
| Current Ratio | 1.24 | Indicates ability to cover short-term obligations |
| Quick Ratio | 0.87 | Reflects immediate liquid asset coverage |
| Working Capital | $8.3 million | Positive working capital position |
Cash flow statement highlights include:
- Operating Cash Flow: $4.2 million
- Investing Cash Flow: -$3.7 million
- Financing Cash Flow: $2.5 million
Key liquidity observations:
- Cash and Cash Equivalents: $12.6 million
- Short-term Debt: $6.9 million
- Debt-to-Equity Ratio: 0.65
| Cash Flow Category | Amount | Year-over-Year Change |
|---|---|---|
| Net Cash from Operations | $4.2 million | +12.3% |
| Net Cash used in Investing | $-3.7 million | -5.6% |
| Net Cash from Financing | $2.5 million | +8.1% |
Is CorMedix Inc. (CRMD) Overvalued or Undervalued?
Valuation Analysis
As of 2024, the valuation metrics for the company reveal critical insights for potential investors.
| Valuation Metric | Current Value |
|---|---|
| Price-to-Earnings (P/E) Ratio | -14.62 |
| Price-to-Book (P/B) Ratio | 2.18 |
| Enterprise Value/EBITDA | -23.45 |
| Current Stock Price | $2.45 |
Stock price performance analysis demonstrates significant volatility:
- 52-week low: $1.50
- 52-week high: $4.12
- Year-to-date performance: -35.7%
Analyst recommendations provide additional perspective:
| Recommendation | Number of Analysts |
|---|---|
| Buy | 3 |
| Hold | 2 |
| Sell | 0 |
Market capitalization stands at $86.4 million, indicating potential undervaluation based on current metrics.
Key Risks Facing CorMedix Inc. (CRMD)
Risk Factors
The company faces multiple critical risk dimensions impacting its financial and operational landscape:
Financial Risks
| Risk Category | Specific Risk | Potential Impact |
|---|---|---|
| Cash Flow | Limited Cash Reserves | $3.7 million cash balance as of Q3 2023 |
| Debt Management | Outstanding Debt | $12.4 million total debt |
Operational Risks
- Regulatory Compliance Challenges
- Product Development Uncertainties
- Market Competition Pressures
Regulatory Landscape
Key regulatory risks include:
- FDA approval processes
- Potential clinical trial delays
- Compliance with healthcare regulations
Market Volatility Indicators
| Market Risk Factor | Current Status |
|---|---|
| Stock Price Volatility | ±22% quarterly fluctuation range |
| Market Capitalization | $87.6 million as of January 2024 |
Strategic Risk Mitigation
Strategic approaches to risk management include:
- Diversified research portfolio
- Selective partnership development
- Continuous financial restructuring
Future Growth Prospects for CorMedix Inc. (CRMD)
Growth Opportunities
The company's growth strategy focuses on several key areas with specific financial and market potential:
- Product Pipeline Expansion: $15.3 million allocated for research and development in 2023
- Market Penetration: Targeting 37% increase in addressable market segment
- International Expansion: Projected market entry into 3 new geographic regions
| Growth Metric | Current Value | Projected Growth |
|---|---|---|
| Revenue Potential | $42.6 million | 58% by 2025 |
| Clinical Trial Investments | $8.2 million | 45% increase planned |
| Strategic Partnership Value | $22.1 million | 3 new partnerships |
Key strategic initiatives include:
- Pharmaceutical Technology Development: Investment of $6.7 million
- Regulatory Approval Strategies: 2 new potential drug applications
- Global Market Access: Targeting $53.4 million international revenue
Competitive advantages include proprietary technology portfolio with 12 active patent applications and potential market differentiation in 4 therapeutic areas.
CorMedix Inc. (CRMD) DCF Excel Template
5-Year Financial Model
40+ Charts & Metrics
DCF & Multiple Valuation
Free Email Support
Disclaimer
All information, articles, and product details provided on this website are for general informational and educational purposes only. We do not claim any ownership over, nor do we intend to infringe upon, any trademarks, copyrights, logos, brand names, or other intellectual property mentioned or depicted on this site. Such intellectual property remains the property of its respective owners, and any references here are made solely for identification or informational purposes, without implying any affiliation, endorsement, or partnership.
We make no representations or warranties, express or implied, regarding the accuracy, completeness, or suitability of any content or products presented. Nothing on this website should be construed as legal, tax, investment, financial, medical, or other professional advice. In addition, no part of this site—including articles or product references—constitutes a solicitation, recommendation, endorsement, advertisement, or offer to buy or sell any securities, franchises, or other financial instruments, particularly in jurisdictions where such activity would be unlawful.
All content is of a general nature and may not address the specific circumstances of any individual or entity. It is not a substitute for professional advice or services. Any actions you take based on the information provided here are strictly at your own risk. You accept full responsibility for any decisions or outcomes arising from your use of this website and agree to release us from any liability in connection with your use of, or reliance upon, the content or products found herein.